Spruce Biosciences Inc. (SPRB) that reached significant study milestones last year, anticipates a year filled with key catalysts in 2024.
This clinical-stage biopharmaceutical company is developing novel therapies for rare endocrine disorders with significant unmet medical need. The lead drug candidate is Tildacerfont, being developed for patients with classic congenital adrenal hyperplasia (CAH) and other diseases characterized by elevated levels of adrenocorticotropic hormone (ACTH).
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com